You searched for Alzheimer's - Page 2 of 17

News and Trends 21 Sep 2022

Hoag’s high hopes for new drug with Alzheimer’s disease trial

Hoag’s Pickup Family Neurosciences Institute is initiating a clinical trial for what it says is a promising new investigational treatment for Alzheimer’s disease (AD). The phase I study will determine the safety and tolerability of a single intravenous (IV) dose and multiple IV doses of ACU193. Hoag is seeking individuals who have memory problems to […]

September 21, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 12 Sep 2022

Liquid-interface assisted SERS could lead to earlier detection of Alzheimer’s

In a new publication in Opto-Electronic Advances, Japanese researchers discussed label-free trace detection of bio-molecules by liquid-interface assisted surface-enhanced Raman scattering (SERS) using a microfluidic chip. SERS has attracted attention in biotechnology. This is due to its high sensitivity to localized surface plasmon resonance of nanostructured metals. Trace detection of bio-molecules with large molecular weight […]

September 12, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 7 Sep 2022

Alzinova announces new positive safety review for Alzheimer’s study

Alzinova AB says a second external safety review has been carried out of its clinical phase 1b study. This resulted in a positive assessment to continue the study as planned. Behind the review is an independent expert group, Data and Safety Monitoring Board (DSMB), which continuously reviews the study. Based on the patients included in […]

September 7, 2022 - 4 minutesmins - By Jim Cornall

Interview 2 Sep 2020

An Alzheimer’s Vaccine Challenged the Consensus for 25 Years

For decades, Alzheimer’s disease research focused on a hypothesis that has increasingly been contested. A team of scientists in Slovakia has been swimming against the tide since the beginning, going for an alternative approach that has only recently started gaining recognition. Research in Alzheimer’s disease has recently been plagued by intense disappointment. For over 25 […]

September 2, 2020 - 8 minutesmins - By Farhan Mitha

alzheimers disease treatment vivoryon therapeutics

News and Trends 24 Oct 2019

German Alzheimer’s Drug Backed with €43M After Biogen’s Surprise Turnaround

The German company Vivoryon Therapeutics has raised €43M on Euronext Amsterdam to fund a phase IIb trial of a drug that could slow the progression of Alzheimer’s disease by blocking toxic forms of the protein amyloid-beta. Vivoryon Therapeutics, previously known as Probiodrug, raised the money using a rights offering and a private placement on Euronext […]

October 24, 2019 - 2 minutesmins - By Jonathan Smith

More News! 23 Sep 2019

AC Immune Gets €28M from Eli Lilly as Alzheimer’s Drug Hits Phase I

AC Immune will receive €27.6M (CHF 30M) from big pharma Eli Lilly as it begins a phase I trial of its first-in-class Alzheimer’s disease drug. This is the first milestone payment in a deal worth up to €1.6B (CHF 1.7B), which Eli Lilly and AC Immune signed to develop drugs for Alzheimer’s and other neurodegenerative […]

September 23, 2019 - 2 minutesmins - By Jonathan Smith

More News! 29 Oct 2018

Plasma Replacement Therapy Promising in Alzheimer’s Patients

A blood plasma replacement therapy from Spanish company Grifols reduced cognitive decline by 61% in patients with moderate Alzheimer’s disease compared with placebo. The researchers monitored the cognitive symptoms of 496 patients with Alzheimer’s disease in the Phase IIb/III trial. Over 14 months, the therapy had no effect in patients with mild Alzheimer’s, but the […]

October 29, 2018 - 2 minutesmins - By Jonathan Smith

News and Trends 25 Jun 2018

Update: Could Epigenetics Treat Alzheimer’s? A Spanish Biotech May Give Us Answers

Update (25/06/2018): Oryzon enrolls first patients in the UK in its clinical trial testing its epigenetic Alzheimer’s drug. The company plans to enroll a total of 90 patients in Spain, France and the UK. Update (14/05/2018): Oryzon has been given approval to expand to France its Phase IIa clinical trial for an epigenetic Alzheimer’s drug. The […]

June 25, 2018 - 3 minutesmins - By Alexander Burik

In Depth 29 May 2018

Clinical Trials in Alzheimer’s Disease Are Failing: What Can Be Done?

With no drugs that can stop the progression of the disease and hundreds of clinical trials failing, new fields of research bring hope to people with Alzheimer’s. As the Western population ages, Alzheimer’s disease is becoming one of the biggest diseases of the 21st century. But despite the efforts of science, the FDA and EMA […]

May 29, 2018 - 6 minutesmins - By Clara Rodríguez Fernández

News and Trends 12 Feb 2018

No Nonsense Boehringer Ingelheim Jettisons Failing Alzheimer’s Disease Drug

Boehringer Ingelheim has ditched its Alzheimer’s drug after it failed to meet the endpoints of a Phase II trial but will continue to look at it for the treatment of schizophrenia. One of Germany’s biggest pharma companies, Boehringer Ingelheim, has given up on the development of its Alzheimer’s drug, BI 409306, which underwent Phase II testing. The […]

February 12, 2018 - 3 minutesmins - By Alex Dale

cognitive disorders syndesi therapeutics 1

News and Trends 1 Feb 2018

New Biotech Launched to Fight Cognitive Impairment Caused by Alzheimer’s

Syndesi Therapeutics has been formed by UCB and a group of investors, including Novo Seeds and V-Bio to develop a group of compounds for cognitive disorders caused by diseases like Alzheimer’s. Syndesi Therapeutics will use of Belgian biotech UCB’s expertise in drug discovery for neurological conditions to develop new therapies in cognitive disorders using a new […]

February 1, 2018 - 3 minutesmins - By Alex Dale

News and Trends 22 Nov 2017

Finnish Scientists Find Brain Cells Involved in Alzheimer’s Disease

Alzheimer’s disease is rapidly increasing in prevalence but we have no effective treatment. But, Finnish Researchers have found a new target to investigate. Researchers at the University of East Finland have found that astrocytes, the cells that support the brain, could play a major role in the pathogenesis of Alzheimer’s disease. The research, published in […]

November 22, 2017 - 3 minutesmins - By Alex Dale

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us